Rocket Lab’s Near-50% Rebound Is Defying a Wave of Price-Target Cuts

Rocket Lab Corp. (NASDAQ:RKLB) shares have rallied about 48% from their Nov. 5 intraday low of $43.89, shrugging off a wave of Wall Street price-target reductions. Five major firms have lowered their price targets since Nov. 10, but investors appear focused on something else: a rapidly expanding business that is securing launch contracts even before its next-generation rocket flies.

Record Backlog Gives Rocket Lab Bulls a Reason to Buy

Rocket Lab’s third-quarter results showed why investors remain optimistic despite execution risks.

The company reported record revenue of $267.8 million, up 73% year over year, while its backlog climbed 52% sequentially to a record $3.57 billion.

A major contributor was Neutron, Rocket Lab’s medium-lift rocket. The company secured more than $515 million in launch contracts during the quarter, covering eight missions across five constellation operators. Its total Neutron backlog has reached 16 missions, and the base launch price has risen to $70 million from $55 million, with several of the new missions sold at that level.

That pricing increase is notable because Neutron’s first launch is now targeted for no earlier than 2027. The rocket has yet to prove itself in flight, but customers are already booking capacity years in advance. CEO Peter Beck has pointed to tightening launch capacity as a key driver of demand.

Five Firms Cut Price Targets but Keep Their Ratings

The rally has unfolded alongside a broad reset in analyst expectations.

Cantor Fitzgerald lowered its price target to $111 from $122, while Piper Sandler cut its target to $58 from $83. Barclays reduced its target to $82 from $85, Needham lowered its forecast to $100 from $120, and Morgan Stanley trimmed its target to $103 from $105.

Importantly, none of the five firms downgraded their existing ratings. Cantor, Barclays, Needham and Morgan Stanley retained bullish ratings, while Piper maintained its Neutral rating.

The distinction matters: analysts are becoming more conservative about Rocket Lab’s valuation without necessarily abandoning its long-term growth prospects. Piper’s $58 target is particularly cautious, sitting below the stock’s Nov. 11 closing price of $66.15.

Neutron’s Delay Remains the Biggest Test

There are legitimate reasons for caution. Rocket Lab reported a $79.6 million net loss in the third quarter, while its fourth-quarter adjusted EBITDA loss forecast was wider than analysts expected. Neutron’s delayed debut also leaves the company with execution risk as investor expectations rise.

Still, Rocket Lab is expanding beyond launch services, with spacecraft manufacturing and government contracts adding to its growth opportunities.

For investors, the next test is whether the company can turn its record backlog into revenue while keeping Neutron development on track. The stock’s rebound suggests investors are willing to look beyond the delay. But delivering on those commitments will determine whether the rally has staying power.

RKLB Price Action: Rocket Lab shares were down 1.83% at $64.94 at the time of publication Thursday, according to Benzinga Pro data.

Photo: USA TODAY Network via Reuters Connect